Baxter International Inc.announced the completion of its acquisition of Baxa Corporation, for a cash consideration of $380 million. Baxa develops pharmacy technology that enhances the efficiency and patient safety of oral and IV dose preparation and delivery.
"The acquisition of Baxa demonstrates Baxter's long-term commitment to nutrition and patient safety and it allows us to offer a broader range of solutions for the safe preparation and delivery of IV medications," said Robert M. Davis, president of Baxter's Medical Products business. "We believe Baxa's expertise in safely preparing IV and oral liquid medications, and their shared commitment toward improving patient care through innovative drug preparation and delivery technology will benefit patients around the world."
To read more about Patient Safety please visit Patient Safety & Quality Healthcare
No comments:
Post a Comment